Introduction
Spontaneous intracerebral hemorrhage (ICH) accounts for approximately 15% of all acute strokes and is the deadliest stroke subtype with one-month mortality rates of 40% [1, 2] . After the first year, more than 75% of all ICH patients are severely disabled or deceased [2] . This makes ICH a major public health problem in need of effective therapies, as no treatment has yet been proven effective.
Initial hematoma volume remains the strongest predictor of 30-day mortality and functional outcome [3] . Hematoma location is another factor influencing both short-and long-term outcome [4] . In addition, approximately 30% of patients continue to bleed and demonstrate significant hematoma expansion during hospitalization, which further aggravates outcome [5, 6] .
Because ICH volume and location are determined upon presentation, hematoma expansion holds the po-tential for being the only modifiable predictor of outcome. Therapies preventing expansion could thus provide a key opportunity to decrease final ICH volume. Previous and ongoing clinical trials have focused on limiting expansion, using approaches such as recombinant factor VIIa (rFVIIa) or aggressive blood pressure reduction [7] [8] [9] . The specific targeting of hematoma expansion in clinical trials has yet to yield improvement of clinical outcome, however [7] . This may be partly related to the difficulty of identifying those individuals most likely to benefit from the intervention, i.e. those who will actually suffer hematoma expansion [10] . It is therefore important to understand the risk factors for expansion as well as its biological underpinnings and treatment opportunities. This review addresses those issues and proposes potential clinical applications and future directions.
Hematoma Expansion
Definitions Different definitions have been used across studies to describe hematoma growth between the initial (baseline) CT and the follow-up CT, normally acquired within 24-72 h after the first CT. Most studies use a dichotomized outcome for hematoma expansion: with an absolute cutoff (typically ≥ 3, ≥ 6, or ≥ 12.5 ml), a proportional cut-off (typically >26 or >33%), or a combination of both [6] . The two largest ongoing clinical trials use >33% or >12.5 ml (INTERACT2 [8] ) and ≥ 33% (ATACH II [9] ) as their dichotomized definition of hematoma expansion.
Imaging
The vast majority of studies assessing hematoma expansion have used CT as imaging modality, mainly because of its widespread availability [11] . Different volumetric assessment techniques are used to measure expansion, including ABC/2, ABC/2 with adjusted C values, planimetry, and 3D volume rendering. It is important to note the differences in accuracy between the different techniques, with the semi-automated techniques being more accurate compared to the ABC/2 method, especially in irregularly shaped hematomas [12] .
CT angiography (CTA) is increasingly used for the diagnosis and prognostication of ICH. CTAs were initially obtained to visualize vascular abnormalities underlying ICH, such as arteriovenous malformations, aneurysms, or neoplasms [13] . They now serve the additional purpose of visualizing contrast extravasation within the hematoma, commonly termed the 'spot sign', which correlates with expansion and poor functional outcome discussed in more detail below [14] [15] [16] .
CT's widespread acute availability makes it the primary diagnostic modality for ICH. However, gradient recalled echo MRI is equally sensitive for diagnosing acute ICH [17] . An advantage of MRI over CT is its ability to detect microbleeds, indicative of underlying vascular disease and a risk factor for recurrent lobar ICH [18, 19] .
Timing
The timing of imaging is essential when assessing hematoma expansion. Because expansion represents an intermediate phase between initial hematoma volume and the final (stabilized) volume, the ability to detect expansion depends on the point at which a patient is scanned within this timeframe. Although early presentation is associated with a higher likelihood of hematoma expansion [20, 21] , a substantial subset of all expanders (up to 48%) present at least 6 h after symptom onset [22] . Predicting and preventing expansion thus appears to be an important goal even in late-presenting patients.
Frequency
The frequency of hematoma expansion differs substantially across different studies, most likely because of variations in definition, time from symptom onset to initial CT, and volumetric assessment techniques. The definition of hematoma expansion influences the frequency of its detection and varies between 13 and 32% in patients presenting within 6 h of symptom onset [6] . Timing further influences expansion frequency; in patients scanned within 3 h of symptom onset, any degree of expansion is seen in up to 73% and significant expansion in approximately one third of patients [5] . In later timeframes, the frequency of significant hematoma expansion decreases to 11% for those presenting between 3 and 6 h of symptom onset, 11% after 6 h, and 20% in patients who are 'found down' with symptoms [22] . The previously described variations in volumetric assessment techniques also account for some of the observed differences in expansion frequency [12] .
Pathophysiology Biology Hematoma expansion is often conceptualized as a single vessel that bursts and continues to bleed, analogous to a bathtub with a persistently running tap. This model is easy to visualize and generally consistent with the higher likelihood of expansion in the early course of the hemorrhage [20, 21] . There is no direct histopathologic support for a single persistently bleeding vessel, however. It is also somewhat difficult to reconcile with the clinical observation that hematoma expansion can occur hours after the initial bleeding [22, 23] .
An alternative 'avalanche' model for hemorrhage expansion was proposed by Dr. C. Miller Fisher in the early 1970's. Based on Dr. Fisher's observation of multiple recently ruptured vessels at the periphery of serially sectioned hematomas, this model describes the process of hematoma growth as secondary mechanical shearing of neighboring vessels caused by expansion of the initial hemorrhage [24] . Several observations add support to this model. One is that hemorrhage volumes tend to occur in a bimodal distribution as either small 'microbleeds' or larger 'macrobleeds' consistent with the feed-forward aspect of the avalanche process [25] . A model of secondary vessel shearing is also indirectly supported by genetic data showing the apolipoprotein E (APOE) ε2 allele to be associated with hematoma expansion in lobar ICH [26] . As this allele correlates with an increased breakdown of vessel walls affected by cerebral amyloid angiopathy, it is reasonable to speculate that it may also increase the walls' fragility to mechanical rupture [27, 28] . Finally, the avalanche model is consistent with the interpretation of the CTA spot sign as sites of active bleeding (visualized as contrast extravasation) following venous contrast injection. Multiple spot signs within a single hematoma are common [29, 30] ( fig. 1 ), suggesting simultaneous bleeding from several surrounding vessels as would be expected in an avalanche of secondary shearing rather than a single persistently bleeding vessel.
Computational Model A recent publication sought to create a computational simulation of the avalanche model that would identify the characteristics of hemorrhages generated by simulated rupture of adjacent vessels surrounding an initial site of bleeding [31] ( fig. 2 ) . The results of the simulation indicated that, under particular ranges of parameters for likelihood of secondary vessel rupture and rate of hemorrhage decay (simulating coagulation), this model would yield a bimodal distribution of microbleeds and macrobleeds similar to that observed in lobar ICH patients [25] . The effect of anticoagulation was further simulated by extending the rate of hemorrhage decay, which in the mod- 198 el led to more macrobleed events, larger final ICH volumes, faster rates of expansion, and prolonged durations of hematoma expansion [31] . This model supports the plausibility of the avalanche model and generates further predictions potentially testable in future studies.
Risk Factors
Several risk factors for hematoma expansion have been identified over the last decade. Initial ICH volume is strongly related to expansion risk: larger hematomas are more likely to expand [32, 33] . Two other risk factors include early presentation after symptom onset [14, 22, 32] and anticoagulation use [26, 34, 35] . As noted above, the possession of an APOE ε2 allele also increases the risk of expansion in lobar ICH [26] . The final important risk factor is the CTA spot sign; a marker of active bleeding that has been studied extensively over the last five years. The spot sign has been shown to be a strong and independent predictor of hematoma expansion, poor functional outcome, and death [14] [15] [16] 36] . The major challenge is its relatively low sensitivity of 51% in the recent prospective PREDICT trial [16] , which highlights the considerable number of patients who will suffer expansion despite the absence of a spot sign on CTA.
Outcome
Expansion of the initial hematoma strongly influences morbidity and mortality. The hazard ratio of mortality goes up by 5% with every 10% increase in ICH volume. In addition, each milliliter absolute increase in volume makes patient outcomes 7% more likely to shift from independence to dependence, as measured by the 6-point modified Rankin Scale [5] . Numerous other studies confirm the relationship of expansion with neurological deterioration, poor functional outcome, and death [6, 20, 37] . These relationships appear to be independent of which definition is used for hematoma expansion [6] . Moreover, data from the INTERACT1 trial suggest a clear dose-response relationship between the magnitude of hematoma expansion and functional outcome and mortality, when using either absolute or proportional definitions of expansion [37] .
Treatment and Ongoing Trials
To date, no individual treatment for ICH has shown benefit in a randomized controlled trial, although specialized treatment provided by a neuroscience ICU does appear to reduce mortality [38] . Because of its strong relationship with outcome and the potential to alter its course, hematoma expansion is an appealing therapeutic target. Candidate treatments aimed at improving ICH outcome -potentially by reducing hematoma expansion -can be divided into medical and surgical interventions.
Medical Interventions
Several medical therapies have been studied in randomized controlled trials over the last decades. In the eighties, corticosteroids were found not to be beneficial in the treatment of supratentorial ICH and were even associated with increased complication rates [39] . The 2008 phase III randomized rFVIIa trial was among the most anticipated studies in the treatment era of ICH. With a phase II trial showing beneficial effects on hematoma expansion, mortality, and functional outcome, the first effective treatment for ICH appeared close [40] . Although the phase III trial confirmed the effect on hematoma expansion, it did not find benefit in clinical outcome [7] . One possible explanation for the absence of clinical benefit is that the majority of patients randomized to rFVIIa were not destined to suffer hematoma expansion, but were nonetheless exposed to this agent's potential thromboembolic complications. This explanation argues for using better selection criteria for identifying those patients who are indeed destined to undergo expansion [10] . Two phase II clinical trials are currently testing the CTA spot sign as such a selection tool for treatment with rFVIIa: STOP-IT (ClinicalTrials.gov NCT00810888) and SPOT-LIGHT (ClinicalTrials.gov NCT01359202).
Another candidate approach to limit hematoma expansion is aggressive blood pressure reduction for acute ICH. Two pilot studies have shown that aggressive lowering of blood pressure is safe and feasible in the acute phase following symptom onset. As a secondary endpoint, hematoma expansion also appeared to be limited in patients treated with the intensive blood pressure regime [41, 42] . The second phase of both trials, INTERACT2 [8] and ATACH II [9] , are currently underway, with the results of INTERACT2 expected in 2013.
Surgical Interventions
Surgical interventions have not been proven beneficial in randomized controlled trials, with the exception of cerebellar ICH [43, 44] . The largest surgical trial, STICH, did not show benefit for unselected ICH patients randomized to early surgery (at a median of 30 h) [45] . Subsequent systematic reviews, however, suggested potential positive effects of surgical evacuation in certain subgroups [46, 47] . STICH II is therefore assessing if early surgery for lobar ICH, within 1 cm of the cortex and without intra-ventricular extension, may be beneficial [48] . Minimally invasive surgical techniques also provide promising evidence for future surgical treatment options in acute ICH [49] [50] [51] . It remains unclear whether the possible benefits of surgical clot removal are related to preventing subsequent expansion or rather to reduced pathogenic effects of the clot itself, such as mass effect or neurotoxicity related to hemoglobin, thrombin, and iron accumulation [52] .
Challenges and Future Directions
Hematoma expansion is an attractive endpoint for clinical trials because of its correlation with outcome and the potential to intervene to prevent its occurrence. Substantial challenges remain, however, which will need to be addressed before successful translation to clinical outcomes.
One major challenge will be to identify conditions under which preventing hematoma expansion actually improves clinical outcome. This point is underlined by the observation that, although both rFVIIa trials found that hematoma expansion could be reduced, functional outcome in the phase III trial was not improved [7, 40] . As it seems unlikely that hematoma expansion is clinically meaningless, the more plausible explanation is that the benefits of reducing expansion may have been outweighed by the thromboembolic risks of rFVIIa, particularly in those subjects who would not have expanded even without active treatment. By this reasoning, therapies that carry risk as well as benefit may need to be focused on selected patients at highest risk for subsequent hematoma expansion.
This consideration raises the second challenge of identifying more reliable predictors of hematoma expansion. Early presentation (within 4-6 h) was used in the blood pressure reduction and rFVIIa trials as a surrogate for expansion, but only up to 40% of those patients actually suffer significant hematoma expansion [20] . The CTA spot sign was found to have a higher positive predictive value of 61% in a recent prospective study, and it might therefore be a better (although still imperfect) predictor of expansion [16, 53] . Identifying more accurate predictors of hematoma expansion thus remains a key research priority.
A third challenge is that those patients at highest risk for expansion may have poor outcomes even if expansion is fully prevented. This concern is raised by the observation that the main risk factors for hematoma expansion, such as baseline ICH volume and anticoagulation use, also independently worsen ICH outcome [3, 34] . Our poor ability to reverse these accompanying factors might be indeed another reason behind the negative results of the phase III rFVIIa trial. This consideration raises the possibility that treatments that go beyond preventing expansion, potentially including surgical hematoma evacuation (as currently tested in the STICH II trial [48] ) or neuroprotective agents to salvage damaged brain tissue (such as deferoxamine [54] ), may be required for demonstrably improved ICH outcome.
A final important consideration regarding hematoma expansion is the window it provides on the broader process of ICH pathogenesis. The expansion that can be measured after clinical presentation presumably represents only the tail end of an event that began with the first rupture of a diseased small vessel and progressively grew into a symptomatic macrobleed [24] . Understanding the mechanisms that underlie this process, such as the secondary rupture of adjacent vessels described above, has the potential to lead not only to acute treatments for use after presentation, but also to novel preventive strategies for keeping small vessel ruptures from evolving into symptomatic macroscopic events.
Although these major challenges are still unsolved, substantial progress has been made over the last decades to better understand and potentially treat hematoma expansion. Hematoma expansion remains the most readily modifiable marker of outcome, and thus an intriguing therapeutic target for intracerebral hemorrhage.
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